Search

everythinglearnresearchcommunity

for

Search:↓

The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.

Brain hormones significantly affect hair color and could potentially be used to prevent or reverse grey hair.

Despite progress in treatment, the exact cause of Alopecia areata is still unknown.

Alopecia areata causes hair loss due to an immune attack on hair follicles, influenced by genetics and environment.

Somatostatin may help protect hair follicles from immune attacks.

New protein changes may be involved in the immune attack on hair follicles in alopecia areata.

Dutasteride works better than finasteride for preventing and treating prostate cancer.

The Foxn1(-/-) nude mouse shows disrupted and expanded skin stem cell areas due to high Lhx2 levels.

B2m-free HLA variants may be a new class of HLA important in immune responses and diseases.

Researchers created a stable rabbit cell line for hair research that doesn't age quickly or become cancerous.

The document concludes that alopecia has significant social and psychological effects, leading to a market for hair loss treatments.

Finasteride treats enlarged prostate and may help with baldness, but effects on sexual function and male fetuses are unclear.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

Low doses of BPA can increase prostate growth and change hormone levels in adult rats.

The congress concluded that misuse of antifungal drugs in South Asia has led to widespread treatment failure, and new approaches and regional cooperation are needed.

Innate lymphoid cells type 1 may contribute to alopecia areata.

Only 40 nm nanoparticles can enter skin cells effectively for potential vaccine delivery.

Inactive stem cells in hair follicles and muscles can avoid detection by the immune system.

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

Delta opioid receptors help regulate touch sensation by reducing neurotransmitter release in the spinal cord.

Notch signaling is essential for healthy skin and hair follicle maintenance.

Developing human skin has immune cells with memory-like features.

It's unclear if cell-based therapies from lipoaspirate devices improve clinical outcomes due to inconsistent data.

Blocking certain pathways with kinase inhibitors may help treat cutaneous lupus erythematosus.

Beta-HPV and MCPyV are linked to certain skin cancers, with ongoing research and vaccine development.

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

Growth factors help hair follicle stem cells grow and stay versatile.

Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.

Trichohyalin may trigger the immune response causing alopecia areata.